Literature DB >> 7521813

Factors affecting the yield of acid-fast sputum smears in patients with HIV and tuberculosis.

R L Smith1, K Yew, K A Berkowitz, C P Aranda.   

Abstract

OBJECTIVE: To evaluate the sensitivity of acid-fast sputum smears in the diagnosis of pulmonary Mycobacterium tuberculosis (MTB).
DESIGN: Retrospective chart and radiographic film review.
SETTING: Department of Veterans Affairs Medical Center in New York City. PATIENTS: All patients with positive sputum cultures for MTB during 1989 to 1991, including 100 with HIV, and 76 without HIV infection. PARAMETERS: The likelihood of a positive acid-fast sputum smear, related to chest radiograph findings, CD4 cell counts, drug sensitivity, and the presence of disseminated disease.
RESULTS: Overall, 60 percent of patients with HIV had positive acid-fast smears, compared with 57 percent of non-HIV-infected patients. A relative absence of cavitary infiltrates did not substantially reduce the frequency of acid-fast smears in patients with and without HIV. Patients with HIV and CD4 count < 50, 50 to 200, and > 200 had positive acid-fast smear rates of 58 percent, 60 percent, and 56 percent, respectively; HIV-infected patients with drug-resistant organisms had 65 percent positive smears. Smear positivity was 96 percent in patients with HIV infection and disseminated MTB,
CONCLUSIONS: Positive acid-fast sputum smears in culture-proven MTB occur with similar frequency in patients with and without HIV. The absence of cavitary disease did not significantly reduce the frequency of positive acid-fast smears. For patients with HIV, the likelihood of a positive smear was also independent of CD4 cell counts and drug resistance. Patients with HIV and disseminated MTB had positive sputum smears in nearly all cases.

Entities:  

Mesh:

Year:  1994        PMID: 7521813     DOI: 10.1378/chest.106.3.684

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  8 in total

1.  Occult miliary tuberculosis in advanced HIV disease.

Authors:  E L Corbett; R N Davidson; S B Lucas; N Shetty; R F Miller
Journal:  Genitourin Med       Date:  1996-06

2.  Pyrexia of undetermined origin in advanced HIV disease.

Authors:  C M Tang; C P Conlon; R F Miller
Journal:  Genitourin Med       Date:  1997-08

Review 3.  HIV and tuberculosis: a deadly human syndemic.

Authors:  Candice K Kwan; Joel D Ernst
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

Review 4.  Improving the diagnosis of tuberculosis: From QuantiFERON to new techniques to diagnose tuberculosis infections.

Authors:  Amy Y Vittor; Joseph M Garland; David Schlossberg
Journal:  Curr HIV/AIDS Rep       Date:  2011-09       Impact factor: 5.071

5.  Increase in anti-tuberculosis drug resistance in Botswana: results from the fourth National Drug Resistance Survey.

Authors:  H J Menzies; G Moalosi; V Anisimova; V Gammino; C Sentle; M A Bachhuber; E Bile; K Radisowa; O Kachuwaire; J Basotli; T Maribe; R Makombe; J Shepherd; B Kim; T Samandari; S El-Halabi; J Chirenda; K P Cain
Journal:  Int J Tuberc Lung Dis       Date:  2014-09       Impact factor: 2.373

6.  Implementation and evaluation of an isoniazid preventive therapy pilot program among HIV-infected patients in Vietnam, 2008-2010.

Authors:  Thuy T Trinh; Dien T Han; Emily Bloss; Thai H Le; Tung T Vu; Anh H Mai; Nhung V Nguyen; Long T Nguyen; Sy N Dinh; Sara Whitehead
Journal:  Trans R Soc Trop Med Hyg       Date:  2015-10       Impact factor: 2.184

7.  Transmission of tuberculosis from smear negative patients: a molecular epidemiology study.

Authors:  E Hernández-Garduño; V Cook; D Kunimoto; R K Elwood; W A Black; J M FitzGerald
Journal:  Thorax       Date:  2004-04       Impact factor: 9.139

8.  Comparative radiological features of disseminated disease due to Mycobacterium tuberculosis vs non-tuberculosis mycobacteria among AIDS patients in Brazil.

Authors:  Rodrigo P dos Santos; Karin L Scheid; Denise Mc Willers; Luciano Z Goldani
Journal:  BMC Infect Dis       Date:  2008-02-29       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.